Touting PhIII success for arthritis drug Taltz, Eli Lilly chases rival Novartis in heated immunology race

Touting PhIII success for arthritis drug Taltz, Eli Lilly chases rival Novartis in heated immunology race

Source: 
Endpoints
snippet: 

Aiming for a new indication to expand the use — and sales — of its psoriatic arthritis drug Taltz, Eli Lilly is spotlighting positive Phase III results Thursday for its blockbuster hopeful against another type of arthritis: ankylosing spondylitis.